top of page
REVERSIBLE FALLOPIAN
TUBE OCCLUSION SYSTEM
Femigard vision - striving for new horizon in female fertility and sterility.
Femiguard Vision
Company ID
COMPANY ID
“Seed” stage
Founded in 2019, backed by Sanara Ventures and the Israeli Innovation Authority
Strong team
Established expertise in medical device development, with top tier industry collaborators
Platform Technology
A novel concept for fallopian tubes occlusion.
Applicable to a wide range
of indications
Raising Capital
Expected during 2022
Supporting clinical validation
IP position
Unique technology protection. establishing significant entry barrier Currently at PCT stage
Femtech
Provide unique medical solution for clinical needs
OUR MISSION
Future Market
Contraception
Non hormonal reversible tubal occlusion in office procedure
Primary Market
IVF
Improving pregnancy implantation success rates in patients with tubal Hydrosalpinx
Contact Us
bottom of page